William K. Oh, M.D.

Associate Professor, Department of Medicine, Harvard Medical School

Associate Physician, Medicine, Brigham And Women's Hospital

Clinical Director, Center for Genitourinary Oncology, Dana-Farber Cancer Institute

Contact Info

William Oh
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: D1230
Phone: 617-632-4524
Fax: 617-632-2165
william_oh@dfci.harvard.edu

Assistant

Kathleen Maclachlan
Administrative Assistant
Center for Genitourinary Oncology
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Phone: 617-632-4524
Fax: 617-632-2165
kathleen_tassi@dfci.harvard.edu

DF/HCC Program Affiliation

Kidney Cancer
Prostate Cancer

Research Abstract

(1) Chemotherapy for hormone refractory prostate cancer.
(2) Multimodality approaches to high risk localized prostate cancer.
(3) New approaches to bladder and renal cancer therapy.
(4) Prostate cancer clinical database.

Publications

Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ.Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen
15289492
Tay MH, Kaufman DS, Regan MM, Leibowitz SB, George DJ, Febbo PG, Manola J, Smith MR, Kaplan ID, Kantoff PW, Oh WK.Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.Ann Oncol 2004 Jun;15(6):97
15151957
Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ,.A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leuk
14669278

Advanced search
DF/HCC Directory Login Update Member Profile Change Account Settings Applying for Membership Benefits Requirements Responsibilities	William K. Oh, M.D. Associate Professor, Department of Medicine, Harvard Medical School Associate Physician, Medicine, Brigham And Women's Hospital Clinical Director, Center for Genitourinary Oncology, Dana-Farber Cancer Institute Contact Info William Oh Dana-Farber Cancer Institute 44 Binney Street Boston, MA, 02115 Mailstop: D1230 Phone: 617-632-4524 Fax: 617-632-2165 william_oh@dfci.harvard.edu Assistant Kathleen Maclachlan Administrative Assistant Center for Genitourinary Oncology Dana-Farber Cancer Institute 44 Binney Street Boston, MA, 02115 Phone: 617-632-4524 Fax: 617-632-2165 kathleen_tassi@dfci.harvard.edu DF/HCC Program Affiliation Kidney Cancer Prostate Cancer Research Abstract (1) Chemotherapy for hormone refractory prostate cancer. (2) Multimodality approaches to high risk localized prostate cancer. (3) New approaches to bladder and renal cancer therapy. (4) Prostate cancer clinical database. Publications Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ.Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen 15289492 Tay MH, Kaufman DS, Regan MM, Leibowitz SB, George DJ, Febbo PG, Manola J, Smith MR, Kaplan ID, Kantoff PW, Oh WK.Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.Ann Oncol 2004 Jun;15(6):97 15151957 Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ,.A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leuk 14669278
Site Map Site Feedback Web Privacy Policy